


PHARMACEUTICAL 2023

♦ KRONOS∙BIO

Kronos Bio Inc. Rank 135 of 446





PHARMACEUTICAL 2023

&KRONOS∙BIO

Kronos Bio Inc. Rank 135 of 446

The relative strengths and weaknesses of Kronos Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kronos Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Kronos Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 123% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	244,291
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,486
Liabilities, Non-Current	28,953
Other Assets	37,662
Other Compr. Net Income	-753
Other Expenses	0
Other Liabilities	0
Other Net Income	3,911
Other Revenues	0
Property and Equipment	12,985
Research and Development	93,715
Selling, General and Administrative Expense	43,400

Output Variable	Value in 1000 USD
Assets	294,938
Liabilities	50,439
Expenses	137,115
Revenues	0
Stockholders Equity	244,499
Net Income	-133,204
Comprehensive Net Income	-133,580
Economic Capital Ratio	166%

